ClinicalTrials.gg
CompletedNCT03120364Updated Apr 19, 2017

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

A Phase 3 interventional study of NBP608 and Zostavax in Herpes Zoster, sponsored by SK Chemicals Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-19.

Sponsored by SK Chemicals Co., Ltd. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Sep 2015, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
824
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Herpes Zoster with a site in Korea, Republic of — 3 open to participants now, 6 under way, 2 of them phase 3. Herpes Zoster · Korea, Republic of.

Enrollment
7th of 23
824 · median 237
Started
2015
the only one that year
Phase 3
12 of 26
1 open now
Registered
11th of 26
by date
Lead sponsor
2 of 26
SK Chemicals Co., Ltd.

Among the 26 studies in Herpes Zoster with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2015, is one of 12 in phase 3, and was the 11th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

3 of the 26 studies in Herpes Zoster with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Herpes Zoster with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 824 healthy subjects (412 subjects per treatment arm) aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Read the detailed description

This is a multi-center, randomized, double blinded, parallel-group study to assess the Immunogenicity and safety of NBP608 compared to Zostavax which are indicated for the prevention of herpes zoster. Total of 824 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned in 1:1 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata.

Total of five visits are scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks after vaccination at Visit 2 and Visit 4 respectively. Safety is monitored 1 week, 6 weeks and 26 weeks after vaccination through Visit 3*, Visit 4 and Visit 5* (* telephone contact)

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Herpes Zoster Vaccine
  • Prevention of Herpes Zoster
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult over aged 50 years
  • Menopause females or females who are confirmed to be negative in a preganacy test on the day of screening and agree to practice for 6 weeks after signing informed concent

Exclusion criteria

Exclusion Criteria:

  • Those with to any component of IP( Product), such as gelatin
  • Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome
  • Those who have received antiviral agents witin 1 month prior to IP vaccination (topical antiviral agent is allowed)
  • Those who have previously received herpes zoster vaccine
  • Those who have a history of herpes zoster
  • Those with congenital or acquired immunodeficiency
  • Those with active untreated tuberculosis
  • Those who have received blood products or immunoglobulin within 3 months prior to IP(Investigational Products) vaccination
  • Those who have received other IPs(Investigational Products) in another clinical study witin 4 weeks prior to IP vaccination in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
824 participants (actual)

Study arms

  • Experimental
    NBP608

    Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm

    Biological: NBP608

  • Active comparator
    Zostavax

    Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm

    Biological: Zostavax

Interventions

  • BiologicalNBP608

    Preparation of Oka/SK strain of live, attenuated zoster virus

  • BiologicalZostavax

    Preparation of Oka/Merck strain of live, attenuated zoster virus

06

What researchers measure

Primary outcomes

  1. GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)

    The geometric mean fold rise of subjects' VZV(Varicella zoster virus) antibody titers of NBP608 from prevaccination to 6weeks postvaccination

    Time frame: 6 weeks after IP(Investigational Product) vaccination

  2. GMR(Geometric Mean Ratio) ratio of NBP608 to Zostavax measured by gpELISA

    Non-inferiority assessment by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax

    Time frame: 6 weeks after IP(Investigational Product) vaccination

Secondary outcomes

  1. VZV-CMI(Varicella Zoster Virus-Cell Mediated Immnogenicity) response measured by IFN-γ(Interferon-gamma) ELISPOT (Enzyme-Linked Immunospot)

    Time frame: 6 weeks after IP(Investigational Product) vaccination

  2. VZV-CMI(Varicella Zoster Virus-Cell Mediated Immnogenicity) response measured by IL-2(Interleukin-2) ELISPOT (Enzyme-Linked Immunospot)

    Time frame: 6 weeks after IP(Investigational Product) vaccination

07

Study locations

1 site
  • Korea University Guro Hospital
    Seoul, Guro-gu 152-703, Korea, Republic of
08

References and documents

Publications

  • Choi WS, Choi JH, Jung DS, Choi HJ, Kim YS, Lee J, Jang HC, Shin EC, Park JS, Kim H, Cheong HJ. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax(R) in healthy adults aged 50 years and older. Vaccine. 2019 Jun 12;37(27):3605-3610. doi: 10.1016/j.vaccine.2019.04.046. Epub 2019 May 20. PubMed 31122860 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Dec 2015, 3 months.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 3 months is below that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 19, 2017
StartActual
Sep 9, 2015
Primary completionActual
Dec 16, 2015
CompletionActual
Apr 28, 2016
Last update
Apr 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03120364
Responsible party
Sponsor
First posted
Apr 19, 2017
Start date
Sep 9, 2015
Primary completion
Dec 16, 2015
Completion
Apr 28, 2016
Last update
Apr 19, 2017

Study contacts

Hee-Jin Cheong, Ph.D
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NBP608

Start the discussion